• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

2015 Annual Business Report

— January 5, 2017

Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66® Cell Line

Read more

— Stock information


— December 9, 2016
Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

Read more

— Financial Calendar

 February 23, 2017
 Preliminary 2016 Results (Revenues, Cash)

 March 23, 2017
 2016 Financial Statements

See all  dates

Webcast on Developing a Vaccine for Lyme



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs

J.P. Morgan 35th Annual Healthcare Conference
San Francisco, US
January 9-12, 2017

Invest Securities BioMed Event
Paris, France
January 26, 2017

10th Kempen Life Sciences Conference
Amsterdam, NL
April 18-19, 2017

Please update your browser...